| Cover | Sep. 13, 2023 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | EXPLANATORY NOTE This amendment to the Current Report on Form 8-K filed by Titan Pharmaceuticals, Inc. (“Titan” or the “Company”) on September 18, 2023 is being filed to amend certain disclosures regarding the Certificate of Designations, Preferences and Rights of Series AA Convertible Preferred Stock. No other changes have been made to the Form 8-K. |
| Document Period End Date | Sep. 13, 2023 |
| Entity File Number | 001-13341 |
| Entity Registrant Name | TITAN PHARMACEUTICALS, INC. |
| Entity Central Index Key | 0000910267 |
| Entity Tax Identification Number | 94-3171940 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 400 Oyster Point Blvd. |
| Entity Address, Address Line Two | Suite 505 |
| Entity Address, City or Town | South San Francisco |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94080 |
| City Area Code | 650 |
| Local Phone Number | 244-4990 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | TTNP |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
